Results 41 to 50 of about 69,031,262 (351)

Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment

Mediators of Inflammation, 2020
COVID-19 is a pandemic disease caused by the new coronavirus SARS-CoV-2 that mostly affects the respiratory system. The consequent inflammation is not able to clear viruses.
S. Cicco, G. Cicco, V. Racanelli, A. Vacca   +3 more
semanticscholar   +1 more source

Azithromycin through the Lens of the COVID-19 Treatment

Antibiotics, 2022
Azithromycin has become famous in the last two years, not for its main antimicrobial effect, but for its potential use as a therapeutic agent for COVID-19 infection.
Georgia G. Kournoutou, G. Dinos
semanticscholar   +1 more source

Listeria monocytogenes bacteremia developed during treatment of COVID‐19

Clinical Case Reports, 2023
Key Clinical Message Listeria monocytogenes is an important pathogen in older patients and immunosuppressed patients, often causing bacteremia. Complications resulting from infections other than COVID‐19 must also be considered during COVID‐19 treatment.
Jin Yamamoto, Keitaro Nakamoto, Teppei Shimasaki, Daisuke Kurai, Takeshi Saraya, Haruyuki Ishii   +5 more
doaj   +1 more source

Anti-inflammatory potential of Quercetin in COVID-19 treatment

Journal of Inflammation, 2021
SARS-CoV-2 is a betacoronavirus causing severe inflammatory pneumonia, so that excessive inflammation is considered a risk factor for the disease. According to reports, cytokine storm is strongly responsible for death in such patients.
A. Saeedi-Boroujeni, M. Mahmoudian-sani
semanticscholar   +1 more source

Safety and outcome of revascularization treatment in patients with acute ischemic stroke and COVID-19: the Global COVID-19 Stroke Registry [PDF]

, 2023
Background and ObjectivesCOVID-19-related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the
Mahmoud, M., Tiu, C., Krajina, A., Maia, C., Michael, M., Beyeler, M., Maali, L., Seo, K.D., Coutinho, J.M., Eichlová, Z., Audebert, H.J., Fuentes, B., Bianco, G., Vuillier, F., Simister, R., Radu, R.A., De Meris, J., Melo, T.P.E., Forlivesi, S., Wrona, P., Gloyer, N.O., Arnold, M., Bandzarewicz, A., Varela, R., Obara, K., Bartosik-Psujek, H., Martins, R.T., Terecoasa, E.O., Stolp, J., Stepien, A., Cereda, C.W., Nalleballe, K., Sieczkowski, B., Gioia, S. la, Masoud, H., Min, J., Zivelonghi, C., Amaya, P., Strambo, D.N., Mansour, O.Y., Havlicek, R., Schwarz, G., Ferrari, J., Abdelkhalek, H., Nguyen, T., Nunes, A.P., Cruz-Culebras, A., Nogueira, R.G., Calleja-Castaño, P., Paula, A., Renú, A., Urbanowski, P., Carrera, E., Jíra, M., Guzinski, M., Dusart, A., Staszewski, J., Vandervorst, F., Ismail, I.I., Castro, P., Broocks, G., Hernández-Fernández, F., Scollo, S.D., Bilik, M., Bach, I., Global Covid-19 Stroke Registry, Nagendra, S., Panea, C., Sykora, M., Sobieszak-Skura, P., Ferrarese, C., Wasilewski, G., Beretta, S., Mikulik, R., Barrientos Guerra, J.D., See, I., Olserová, A., Piotin, M., Stolze, L.J., Petrescu, S., Ghoreishi, A., Ostos, F., Malheiro, S., Sangalli, D., Pérez-de-la-Ossa, N., Meira, T., Diamanti, S., Vera, R., Baumgartner, P., Ayo-Martin, O., Roubec, M., Machado, R., García-Madrona, S., Cviková, M., Tiu, V., Khawaja, A.M., Altersberger, V., Sramek, M., Lemmens, R., Rodríguez-Vázquez, A., Tomek, A., Ostry, S., Khandelwal, P., Siebert, E., Ong, M., Magriço, M., Sibon, I., Gross, H., Maïer, B., Perez-Sanchez, S., Schaefer, J.H., Bonati, L., Palouskova, H., Meris, J. de, Skoloudík, D., Machado, E., Rentzos, A., Flottmann, F., Skoda, O., Homa, T., Ntaios, G., Dorobat, B., Wetzel, S., Babici, D., Abbas, R., Gentile, M., Min, J.Y., Hlaing, T., Tejada-Meza, H., Vodret, F.R., Maly, P., Pezzini, A., Sienkiewicz-Jarosz, H., Abraham, M.G., Rigual, R., Nordanstig, A., Martín-Jiménez, P., Sabetay, S.I., Gensicke, H., El Naamani, K., Caetano, R., Cano-Nigenda, V., Marto, J.P., Rutkowska, I., Alonso-de-Leciñana, M., Hruby, R., Pereira, L., Guerra, J.D.B., Werring, D., Salmeen, A., Escalard, S., Wlodarczyk, E., Tomaszewska-Lampart, I., Switonska, M., Kaur, N., Chamorro, A., Zwiernik, J., Dias, M.C., Sabben, C., Pansky, M., Al-Hashel, J., Azevedo, E., Migliaccio, L., Alves, J.N., Rutgers, M.P., Montaner, J., Nolte, C., Liegey, J.S., Bellante, F., Flores-Pina, B., Ferreira, P., Naamani, K. el, Chebl, A., De Raedt, S., Tjoumakaris, S., Guilmot, A., El-Samahy, H., Kovar, M., Fiksa, J., Wijngaard, I. van den, Mencl, P., Ozdemir, A., Czlonkowska, A., Serrano-Ponz, M., Strambo, D., Lang, W.L., Negrila, A., Knoflach, M., Wegener, S., Muñoz-Narbona, L., Hurtikova, E., Nowak, M., Bolognese, M., Demeestere, J., Peters, N., Sajeva, G., Ramos, J.N., Jood, K., Trakal, L., Karlinski, M.A., Frisullo, G., Hovingh, M., Onteddu, S., Nederkoorn, P., Dorobek, M., Arango, A., Pinho E Melo, T., Salerno, A., Cappellari, M., Mohamed, G.A., Khan, M., Krajícková, D., Slowik, A., Rodrigues, M., Herzig, R., Correia, M.A., Arauz, A., Machi, P., Cuisenier, P., Gizewski, E.R., Sagarra-Mur, D., Sawczynska, K., Jurak, L., Abdalkader, M., Charbonnier, G., Matute, M.C., Vences, M.A., Pereira-Fonseca, A., Bohmann, F.O., Wiacek, M., Simunek, L., Bochynska, A., Nowakowska-Kotas, M., Ferreira-Pinto, J., Seners, P., van den Wijngaard, I., Tsai, J.P., Gaikwad, A., Tsai, J., Zedde, M., Ribeiro, L., Lang, W., Pernicka, M., Jansky, P., Georgiopoulos, G., Llanos, N., Vinklárek, J., La Gioia, S., Debiec, A., Nguyen, T.N., Legris, L., Segura, T., Zielinska-Turek, J., Kristoffersen, E.S., Klein, P., Jabbour, P., Díaz-Otero, F., Pascarella, R., Sessa, M., Labuz-Roszak, B.M., Albuquerque, L., Mayer-Suess, L., Rajamani, K., Hakemi, M., Zini, A., Slovák, M., Sargento-Freitas, J., González-Ortega, G., Marnat, G., Budrewicz, S., Raedt, S. de, Rocha, M., Yalung, P.M., Marcheselli, S., Díez-Tejedor, E., Araujo, A.P., Michel, P.   +276 more
core   +1 more source

Ayurvedic evaluation and treatment of Covid 19: A case report

Journal of Ayurveda and Integrative Medicine, 2022
COVID-19 patients, with underlying comorbidities are observed to develop complications. Studies have shown that hypertension (one of the comorbidities) is a risk factor for patients with severe COVID-19.
Abhijeet Shirkande, Ankita Shirkande
doaj   +1 more source

Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment

The Journal of pharmacy and pharmacology, 2021
Objectives Viral outbreaks are a frequent concern for humans. A great variety of drugs has been used to treat viral diseases, which are not always safe and effective and may induce adverse effects, indicating the need for new antiviral drugs extracted ...
Nicolas Ripari, A. A. Sartori, Mariana da Silva Honorio, F. L. Conte, K. I. Tasca, K. B. Santiago, J. M. Sforcin   +6 more
semanticscholar   +1 more source

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

, 2022
BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. DESIGN: ACTIV-6 is an ongoing, decentralized,
Boulware, David R., Stewart, Thomas G., Adam, Stacey J., Castro, Mario, Lindsell, Christopher J., Hanna, George, Ruiz-Unger, Juan, Singh, Upinder, Gentile|, Hernandez, Adrian F., Wilder, Rhonda, Thicklin, Florence, McTigue, Kathleen, Ginde, Adit A., Bramante, Carolyn, DeLong, Allison, Felker, G. Michael, Dolor, Rowena J., McCarthy, Matthew W., Wilson, Sybil, Sulkowski, Mark, Collins, Sean, Dunsmore, Sarah E., Jayaweera, Dushyantha, Remaly, April, Gentile, Nina, Naggie, Susanna, Shenkman, Elizabeth   +27 more
core   +1 more source

Review of COVID-19 Treatment.

Journal of research in pharmacy practice, 2020
Many contagious diseases, such as plague or cholera, played a role in changing the pathway of history. In this respect, although coronavirus was not as dangerous as novel diseases such as swine flu and Ebola, the spread and the power of coronavirus infiltration caused public fear across the world.
Somayeh Sadeghi, Mahnaz Momenzadeh, Peiman Nasri, Mina Nickpour   +3 more
openaire   +3 more sources

Niclosamide—A promising treatment for COVID‐19 [PDF]

British Journal of Pharmacology, 2022
Vaccines have reduced the transmission and severity of COVID‐19, but there remains a paucity of efficacious treatment for drug‐resistant strains and more susceptible individuals, particularly those who mount a suboptimal vaccine response, either due to underlying health conditions or concomitant therapies.
Shivani Singh, Anne Weiss, James Goodman, Marie Fisk, Spoorthy Kulkarni, Ing Lu, Joanna Gray, Rona Smith, Morten Sommer, Joseph Cheriyan   +9 more
openaire   +2 more sources